| Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi‐institutional retrospective study Y Nakamura, R Tanaka, Y Asami, Y Teramoto, T Imamura, S Sato, ... The Journal of dermatology 44 (2), 117-122, 2017 | 201 | 2017 |
| Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma H Inoue, JH Park, K Kiyotani, M Zewde, A Miyashita, M Jinnin, Y Kiniwa, ... Oncoimmunology 5 (9), e1204507, 2016 | 130 | 2016 |
| Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity R Tanaka, N Okiyama, M Okune, Y Ishitsuka, R Watanabe, J Furuta, ... Journal of dermatological science 86 (1), 71-73, 2017 | 123 | 2017 |
| Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab Y Fujisawa, K Yoshino, A Otsuka, T Funakoshi, T Fujimura, Y Yamamoto, ... Journal of Dermatological Science 88 (2), 225-231, 2017 | 98 | 2017 |
| Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study T Fujimura, Y Sato, K Tanita, Y Kambayashi, A Otsuka, Y Fujisawa, ... Oncotarget 9 (21), 15542, 2018 | 96 | 2018 |
| Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies Y Nakamura, R Tanaka, H Maruyama, Y Ishitsuka, N Okiyama, ... Japanese journal of clinical oncology 49 (5), 431-437, 2019 | 88 | 2019 |
| Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case report R Tanaka, H Maruyama, Y Tomidokoro, K Yanagiha, T Hirabayashi, ... Japanese Journal of Clinical Oncology 46 (9), 875-878, 2016 | 88 | 2016 |
| Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma Y Honda, A Otsuka, S Ono, Y Yamamoto, JA Seidel, S Morita, M Hirata, ... Oncoimmunology 6 (1), e1253657, 2017 | 76 | 2017 |
| Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients Y Fujisawa, K Yoshino, A Otsuka, T Funakoshi, H Uchi, T Fujimura, ... Journal of Dermatological Science 89 (1), 60-66, 2018 | 63 | 2018 |
| Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease R Tanaka, Y Sasajima, H Tsuda, K Namikawa, A Tsutsumida, F Otsuka, ... British Journal of Dermatology 168 (6), 1259-1266, 2013 | 59 | 2013 |
| Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab R Tanaka, Y Fujisawa, I Sae, H Maruyama, S Ito, N Hasegawa, I Sekine, ... Japanese journal of clinical oncology 47 (2), 175-178, 2017 | 58 | 2017 |
| BRAF V600 mutations and pathological features in Japanese melanoma patients N Yamazaki, R Tanaka, A Tsutsumida, K Namikawa, H Eguchi, W Omata, ... Melanoma research 25 (1), 9-14, 2015 | 53 | 2015 |
| Nivolumab-induced thyroid dysfunction R Tanaka, Y Fujisawa, H Maruyama, Y Nakamura, K Yoshino, M Ohtsuka, ... Japanese Journal of Clinical Oncology 46 (6), 575-579, 2016 | 50 | 2016 |
| Immune-related adverse events in various organs caused by immune checkpoint inhibitors N Okiyama, R Tanaka Allergology International 71 (2), 169-178, 2022 | 46 | 2022 |
| Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma K Namikawa, A Tsutsumida, R Tanaka, J Kato, N Yamazaki International journal of clinical oncology 19, 198-203, 2014 | 46 | 2014 |
| Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019 Y Nakamura, J Asai, H Igaki, T Inozume, K Namikawa, A Hayashi, ... The Journal of Dermatology 47 (2), 89-103, 2020 | 36 | 2020 |
| Serum level of soluble CD163 may be a predictive marker of the effectiveness of nivolumab in patients with advanced cutaneous melanoma T Fujimura, Y Sato, K Tanita, Y Kambayashi, A Otsuka, Y Fujisawa, ... Frontiers in oncology 8, 530, 2018 | 35 | 2018 |
| Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6 R Tanaka, Y Ichimura, N Kubota, A Saito, Y Nakamura, Y Ishitsuka, ... Communications Biology 3 (1), 571, 2020 | 34 | 2020 |
| Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents R Tanaka, K Yonemori, A Hirakawa, F Kinoshita, N Takahashi, ... The oncologist 21 (4), 508-513, 2016 | 34 | 2016 |
| Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash Y Ichimura, R Konishi, M Shobo, S Inoue, M Okune, A Maeda, R Tanaka, ... Rheumatology 61 (3), 1222-1227, 2022 | 33 | 2022 |
